Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (11-20 of 452) with videos related to

Pageof 46
Sort By:
Seminars in Oncology|April 9, 2005
Palliative chemotherapy: historical perspective, applications, and controversiesIlene Browner, Michael A Carducci
Expert Opinion on Pharmacotherapy|June 5, 2003
Pharmacotherapy of hormone refractory prostate cancer: new developments and challengesEli Rosenbaum, Michael A Carducci
Idrugs : the Investigational Drugs Journal|February 8, 2005
Focus on deacetylation for therapeutic benefitShabana Shabbeer, Michael A Carducci
Nature Reviews. Urology|August 7, 2009
Intermittent androgen deprivation--questions remainDaniel Keizman, Michael A Carducci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Targeting bone metastasis in prostate cancer with endothelin receptor antagonistsMichael A Carducci, Antonio Jimeno
BJU International|April 26, 2000
The role of endothelin-1 and endothelin receptor antagonists in prostate cancerJ B Nelson, M A Carducci
Clinical Prostate Cancer|January 8, 2005
Early use of chemotherapy in conjunction with radical prostatectomyJoshi J Alumkal, Michael A Carducci
Expert Opinion on Investigational Drugs|January 6, 2010
Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effectsEmmanuel S Antonarakis, Michael A Carducci
Expert Opinion on Investigational Drugs|August 18, 2018
Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directionsPedro Isaacsson Velho, Michael A Carducci
Medicina Nei Secoli|January 1, 1976
[Therapeutic guidlines in the territory of Otranto in the middle of the 19th century: considerations on relations to Tarantine medicine]C Sebastio, A Carducci, R Talamonti
Pageof 46

Showing results (11-20 of 452) with videos related to

Sort By:
Pageof 46
Seminars in Oncology|April 9, 2005
Palliative chemotherapy: historical perspective, applications, and controversiesIlene Browner, Michael A Carducci
Expert Opinion on Pharmacotherapy|June 5, 2003
Pharmacotherapy of hormone refractory prostate cancer: new developments and challengesEli Rosenbaum, Michael A Carducci
Idrugs : the Investigational Drugs Journal|February 8, 2005
Focus on deacetylation for therapeutic benefitShabana Shabbeer, Michael A Carducci
Nature Reviews. Urology|August 7, 2009
Intermittent androgen deprivation--questions remainDaniel Keizman, Michael A Carducci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Targeting bone metastasis in prostate cancer with endothelin receptor antagonistsMichael A Carducci, Antonio Jimeno
BJU International|April 26, 2000
The role of endothelin-1 and endothelin receptor antagonists in prostate cancerJ B Nelson, M A Carducci
Clinical Prostate Cancer|January 8, 2005
Early use of chemotherapy in conjunction with radical prostatectomyJoshi J Alumkal, Michael A Carducci
Expert Opinion on Investigational Drugs|January 6, 2010
Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effectsEmmanuel S Antonarakis, Michael A Carducci
Expert Opinion on Investigational Drugs|August 18, 2018
Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directionsPedro Isaacsson Velho, Michael A Carducci
Medicina Nei Secoli|January 1, 1976
[Therapeutic guidlines in the territory of Otranto in the middle of the 19th century: considerations on relations to Tarantine medicine]C Sebastio, A Carducci, R Talamonti
Pageof 46